Global Ovarian Cancer Market Assessment 2019-2029 - Roche Will Continue to Dominate as the Single Largest Player with Approx. 31% of Total Market Revenue in 2029

DUBLIN, May 13, 2020 /PRNewswire/ -- The "Ovarian Cancer: Market Forecast Report 2019-2029" report has been added to's offering.

Over the 10-year forecast period for Ovarian Cancer (OC) from 2019 to 2029, we expect:

    --  A total market growth from $1.1billion to $2.8billion
    --  A major shift in treatment paradigms with the adoption of a diverse
        range of targeted therapies in a category where the broad standard of
        care for most patients has been platinum-based regimens.
    --  Rapid adoption of PARPi and PD-1/PD-L1 targeting regimens and the
        emergence of first in class therapies (e.g. P53 activator APR-246,
        GAS-6i, tisotumab vedotin, oncolytic virus ONCOS-102 and cancer
    --  Targeted therapies will drive longer treatment duration to deliver
        better treatment outcomes (evidenced in clinical trial results), offer
        better value and command premium pricing.
    --  Roche will continue to dominate the market as the single largest player
        with approx. 31% of total market revenue in 2029 (down from 48% in
        2019). Tecentriq (atezolizumab, PD-L1) gaining approval in OC in 2021
        will offset some of the impact from loss of market protection on Avastin
        (bevacizumab) in 2019.
    --  Generics to increase in total market revenue share from 18% to 25% by
        2029 (driven by loss of exclusivity events).
    --  Approximately 30% of the remaining market revenue will be generated by
        current OC drug manufacturers AstraZeneca, Tesaro and Clovis
        Pharmaceuticals, with the remaining share being generated by new market
        entrants such as Merck, Genmab and Aprea Therapeutics.

Key Topics Covered

Forecast Overview

Disease Overview

    --  Introduction
    --  Classification of Ovarian Cancer
    --  Histopathology and Therapy-Specific Disease Classification
    --  Risk Factors & Prevention
    --  Diagnosis of the Disease
    --  Patient & Clinical Management Guidelines (ESMO)
    --  Patient & Clinical Management Flow developed for the forecast using NCCN
        and ESMO guidelines

Treatment Landscape - Overview

    --  Molecules used in Ovarian Cancer Therapy
    --  Regimens in Ovarian Cancer Therapy
    --  Share of Patients Initiating Treatment per Line of Therapy

Market Forecast

    --  Total Market Forecast
    --  Market Forecast Revenue by Line of Therapy
    --  Revenue Forecast by Patient Segments (BRCA vs Wild Type)
    --  Patient Share Initiating Regimen per Line of Therapy
        --  Adjuvant
        --  First Line Metastatic
        --  Second Line Platinum Sensitive
        --  Second Line Platinum-Resistant
        --  Maintenance Lines
    --  Drug Class Market Positioning
        --  Drug Class Market Shares by Lines of Therapy
    --  Manufacturer Market Positioning
        --  Forecast Data
        --  Forecast Commentary

Market Events

    --  New Product Launches
    --  Important New Product Launches
    --  Loss of Market Protection


    --  List of Molecules used in Ovarian Cancer

Dynamic Patient Flow Methodology for Forecast

New Product Assumptions Methodology

Companies Mentioned

    --  AstraZeneca
    --  Roche
    --  Tesaro

For more information about this report visit

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager

or E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:

SOURCE Research and Markets